<DOC>
	<DOC>NCT01806623</DOC>
	<brief_summary>As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas. However in Japan oral therapy with antifungal triazole such as Fluconazole has not been approved, and topical therapies such as vaginal tablets, pessary and cream are used clinically. The purpose of this trial is to confirm the efficacy and safety of single oral administration of fluconazole 150 mg for the treatment of vulvovaginal candidiasis in Japanese patients.</brief_summary>
	<brief_title>The Study Of Fluconazole For Vulvovaginal Candidiasis</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Vulvovaginal</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Patients with clinical symptoms and signs of vulvovaginal candidiasis. Patients tested positive for Candida by fungal culture. Patients who can agree not to have intercourse up to 28 days after dosing. Patients with a history of hypersensitivity to fluconazole. Patients with severe renal dysfunction. Patients with liver disorder.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>